EP Patent

EP1492874B1 — Multigenic vector plasmids and methods for increasing expression of recombinant polypeptides

Assigned to Xoma Technology Ltd USA · Expires 2011-01-19 · 15y expired

What this patent protects

The present invention provides novel methods and materials for increasing the expression of recombinant polypeptides. Methods and materials of the invention allow increased expression of transcription units that include recombinant DNA sequences which encode polypeptides of inter…

USPTO Abstract

The present invention provides novel methods and materials for increasing the expression of recombinant polypeptides. Methods and materials of the invention allow increased expression of transcription units that include recombinant DNA sequences which encode polypeptides of interest. The present invention provides expression vectors which contain multiple copies of a transcription unit encoding a polypeptide of interest separated by at least one selective marker gene and methods for sequentially transforming or trasnfecting host cells with expression vectors to increase transcription unit dosage and expression.

Drugs covered by this patent

Patent Metadata

Patent number
EP1492874B1
Jurisdiction
EP
Classification
Expires
2011-01-19
Drug substance claim
No
Drug product claim
No
Assignee
Xoma Technology Ltd USA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.